Metipranolol is a beta-adrenergic antagonist used for the reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors.
- Mechanism
- Curator reviewed
Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.
- Primary indication
- Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.Curator reviewed · 2 structured indications
- Formula / weight
- C17H27NO4 · 309.4006 g/mol (avg)
- First approval
- United States, 1989
- Code names
- BM-01.004 · VUAB-6453
Resolves to
BQIPXWYNLPYNHW-UHFFFAOYSA-NSMILESCC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Metipranolol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account